Full-Time

Scientist I

Conjugation Development

Posted on 8/22/2024

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$125k - $130kAnnually

Entry, Junior, Mid

San Carlos, CA, USA

This position is onsite in San Carlos, California.

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • B.S. in chemistry, biochemistry, or related field with 8+ years of relevant industry experience; MS with 5+ years of relevant industry experience, or Ph.D. with two years of relevant industry experience.
  • Experience with laboratory-scale protein purification methods such as dialysis, diafiltration and size-exclusion chromatography. Experience with tangential flow filtration (TFF) is desirable.
  • Working knowledge of analytical methods including colorimetric assays, size-exclusion chromatography (SEC), and SDS-PAGE for characterization of reaction products.
  • Experience performing protein conjugation reactions is desirable.
  • Experience with chemical modification of polysaccharides is desirable.
  • Attention to detail and excellent organizational skills.
  • Strong interpersonal skills; ability to communicate effectively both verbally and in written formats.
  • Self-starter; ability to work in a fast-paced, cross-functional environment and collaborate effectively with other team members.
  • Enthusiasm to learn the new skills and techniques necessary to tackle problems outside of current area of expertise.
Responsibilities
  • Optimize and troubleshoot multi-step syntheses of protein-polysaccharide conjugates.
  • Purify polysaccharides and conjugates using a variety of methods including dialysis, size-exclusion chromatography, and tangential flow filtration (TFF).
  • Analyze polysaccharides and conjugates with methods including colorimetric assays, HPLC assays, and SEC-MALS.
  • Maintain highly organized records to enable optimization and assessment of reproducibility.
  • Track inventory of reagents critical to conjugation development, and make purchases to replenish when necessary.
  • Attend team meetings ready to provide updates on conjugation development progress.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while stimulating an immune response. Unlike traditional cell-based methods, their approach allows for the development of broad-spectrum vaccines. Vaxcyte's goal is to provide effective vaccines that can significantly reduce the impact of bacterial diseases on global health.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

2%

1 year growth

2%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • FDA Breakthrough Therapy designation for VAX-24 may accelerate its market entry.
  • Global pneumococcal vaccines market is projected to grow at a CAGR of 5.6% until 2030.
  • Recent $1.5 billion public offering strengthens Vaxcyte's financial position for future developments.

What critics are saying

  • Competition from mRNA technology developers like Moderna and BioNTech is intense.
  • Potential regulatory delays could impact Vaxcyte's clinical trial timelines.
  • Intellectual property disputes may arise over cell-free protein synthesis technology.

What makes Vaxcyte unique

  • Vaxcyte uses a proprietary cell-free protein synthesis platform, XpressCF™, for vaccine development.
  • Their lead product, VAX-24, targets 24 strains of Streptococcus pneumoniae bacteria.
  • Vaxcyte focuses on broad-spectrum vaccines for bacterial infections, unlike traditional methods.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Stock Options

Remote Work Options

INACTIVE